EMEA-001501-PIP02-13-M07
Table of contents
Key facts
| Invented name |
Dupixent
|
| Active substance |
dupilumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0039/2022
|
| PIP number |
EMEA-001501-PIP02-13-M07
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of asthma
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Sanofi-Aventis Recherche & Développement
Tel. +33 169745695 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|